Skip to main content

BIO-TECHNE Corp cash and equivalents

  • TECH · Nasdaq
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$72.80−0.05%Close 13 Nov 2026

BIO-TECHNE Corp's cash and equivalents was $265 million for fiscal year 2026 (the twelve months to 30 Jun 2026), up 63.2% from fiscal 2025.

In the first quarter of fiscal 2027 (the three months to 30 Sep 2026) it was $350 million, up 141% from a year earlier.

From BIO-TECHNE Corp's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026.

Fiscal 2026
$265M
+63.2%
Q1 FY2027
$350M
+141% on a year
Growth over 9 years
+12.5%
a year, FY 2017–FY 2026

Cash and equivalents by fiscal year

$91.6MFY 2017$122MFY 2018+33.2%$101MFY 2019−17.3%$147MFY 2020+45.3%$199MFY 2021+35.8%$173MFY 2022−13.3%$181MFY 2023+4.6%$152MFY 2024−15.9%$162MFY 2025+6.8%$265MFY 2026+63.2%

Change on the year before, under each year. From FY 2017 to FY 2026, BIO-TECHNE Corp's cash and equivalents went from $91.6 million to $265 million, a compound annual change of +12.5%; FY 2026 is the highest of the period.

BIO-TECHNE Corp cash and equivalents, fiscal years
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Cash and equivalents$91.6M$122M$101M$147M$199M$173M$181M$152M$162M$265M
Period end30 Jun 201730 Jun 201830 Jun 201930 Jun 202030 Jun 202130 Jun 202230 Jun 202330 Jun 202430 Jun 202530 Jun 2026

Cash and equivalents by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

BIO-TECHNE Corp cash and equivalents, fiscal quarters
PeriodQ2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Cash and equivalents$178M$141M$162M$145M$173M$210M$265M$350M
Period end31 Dec 202431 Mar 202530 Jun 202530 Sep 202531 Dec 202531 Mar 202630 Jun 202630 Sep 2026

How cash and equivalents is measured

Cash and equivalents is the cash the company holds at the end of the period and the investments it can turn into cash within three months. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

BIO-TECHNE Corp's other figures

Cash and equivalents of comparable companies

Everything on TECH, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.